CryoPort Stock Forecast, Price & News

CryoPort's stock was trading at $16.62 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CYRX stock has increased by 177.0% and is now trading at $46.03.
View which stocks have been most impacted by COVID-19.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CryoPort in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for CryoPort.

CryoPort is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for CryoPort.

CryoPort Inc (NASDAQ:CYRX) announced its quarterly earnings results on Thursday, August, 6th. The consumer goods maker reported ($0.15) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.04. The consumer goods maker earned $9.39 million during the quarter, compared to the consensus estimate of $8.93 million. CryoPort had a negative net margin of 60.97% and a negative return on equity of 18.89%. The company's quarterly revenue was up 11.0% compared to the same quarter last year. During the same period last year, the company posted ($0.08) earnings per share.
View CryoPort's earnings history.

6 Wall Street analysts have issued 1 year price objectives for CryoPort's shares. Their forecasts range from $25.00 to $66.00. On average, they expect CryoPort's stock price to reach $42.33 in the next year. This suggests that the stock has a possible downside of 8.0%.
View analysts' price targets for CryoPort.

CryoPort saw a decrease in short interest in August. As of August 31st, there was short interest totaling 6,420,000 shares, a decrease of 18.5% from the August 15th total of 7,880,000 shares. Based on an average daily trading volume, of 784,300 shares, the short-interest ratio is currently 8.2 days.
View CryoPort's Short Interest.

Some companies that are related to CryoPort include ACADIA Pharmaceuticals (ACAD), Perrigo (PRGO), Bausch Health Companies (BHC), Emergent Biosolutions (EBS), BridgeBio Pharma (BBIO), Ultragenyx Pharmaceutical (RARE), United Therapeutics (UTHR), Zai Lab (ZLAB), HUTCHISON CHINA/S (HCM), Arrowhead Pharmaceuticals (ARWR), Blueprint Medicines (BPMC), Legend Biotech (LEGN), Allakos (ALLK), Arena Pharmaceuticals (ARNA) and FibroGen (FGEN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other CryoPort investors own include Gilead Sciences (GILD), Advanced Micro Devices (AMD), Micron Technology (MU), Taiwan Semiconductor Mfg. (TSM), NVIDIA (NVDA), Amarin (AMRN), Crispr Therapeutics (CRSP), Enterprise Products Partners (EPD), Exelixis (EXEL) and Sorrento Therapeutics (SRNE).

CryoPort trades on the NASDAQ under the ticker symbol "CYRX."

CryoPort's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.34%), Victory Capital Management Inc. (2.68%), TimesSquare Capital Management LLC (1.99%), GW&K Investment Management LLC (1.79%), FMR LLC (1.02%) and Granite Investment Partners LLC (0.99%). Company insiders that own CryoPort stock include Jerrell Shelton, Richard J Berman and Robert Stefanovich.
View institutional ownership trends for CryoPort.

CYRX stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., TimesSquare Capital Management LLC, Creative Planning, Essex Investment Management Co. LLC, Silvercrest Asset Management Group LLC, Handelsbanken Fonder AB, Taylor Wealth Management Partners, and Penbrook Management LLC. Company insiders that have sold CryoPort company stock in the last year include Richard J Berman, and Robert Stefanovich.
View insider buying and selling activity for CryoPort.

CYRX stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Granite Investment Partners LLC, Bamco Inc. NY, SG Americas Securities LLC, Great Lakes Advisors LLC, Vanguard Group Inc., Artal Group S.A., and Marshall Wace LLP.
View insider buying and selling activity for CryoPort.

Shares of CYRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CYRX stock can currently be purchased for approximately $46.03.

CryoPort has a market capitalization of $1.78 billion and generates $33.94 million in revenue each year. The consumer goods maker earns $-18,330,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

The official website for CryoPort is www.cryoport.com.

CryoPort's mailing address is 112 Westwood Place Suite 350, Brentwood TN, 37027. The consumer goods maker can be reached via phone at 949-470-2300 or via email at [email protected]